Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | EVP & Chief Info Officer | August 10, 2016 | August 10, 2016 |
| Zapata Quantum, Inc.ZPTA · Entity 6486 | Director | May 01, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date August 10, 2016 · Filed August 10, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,083 |
Reported balance
After 2016-08-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-08-10 · Sale · Disposed 3,000 · Balance 14,083 F1: Holdings include shares acquired in dividend reinvestment transactions. |
| Common Stock - 401(k) PlanSEC Table I · non-derivative | IndirectBy 401(k) | 5,859.5439 |
Reported balance
Holding disclosure · report date 2016-08-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,859.5439 F2: Holdings include shares acquired and dividends earned through July 8, 2016, in the Merck U.S. Savings Plan, a 401(k) plan. In addition, since the date of the reporting person's last ownership report, shares of Merck & Co., Inc. common stock within the 401(k) plan were disposed pursuant to a domestic relations order. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include shares acquired in dividend reinvestment transactions.
F2: Holdings include shares acquired and dividends earned through July 8, 2016, in the Merck U.S. Savings Plan, a 401(k) plan. In addition, since the date of the reporting person's last ownership report, shares of Merck & Co., Inc. common stock within the 401(k) plan were disposed pursuant to a domestic relations order.
Zapata Quantum, Inc.
Report date May 01, 2026 · Filed May 07, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,626,288 |
Reported balance
Holding disclosure · report date 2026-05-01 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 32,626,288 F1: 32,500,000 of the shares of restricted stock vest in equal monthly installments over a two-year period. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2031-02-04 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-01 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance Not disclosed F2: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2033-07-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-01 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance Not disclosed F3: The stock options are fully vested and exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.08 · Expires 2030-10-09 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-01 · row 7
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 7 · Balance Not disclosed F6: The grant of stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The stock options shall vest in equal monthly increments over two years, with the first vesting date to occur on November 9, 2025, subject to continued service as a director of the Issuer on each applicable vesting date and the execution of the Issuer's Stock Option Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-01 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance Not disclosed F4: Restricted stock units convert into shares of common stock on a one-for-one basis. The restricted stock units will vest in three equal installments, with 25,000 shares of common stock vesting on October 10, 2024, 25,000 shares of common stock vesting on January 10, 2025, and 25,000 shares vesting on the date of the 2025 annual meeting of the Issuer's stockholders. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2026-06-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-01 · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · Balance Not disclosed F5: The Reporting Person purchased a convertible promissory note in the principal amount of $100,000 and an accompanying five-year warrant to purchase 1,250,000 shares of common stock, for a total purchase price of $100,000. The conversion price of the note and exercise price of the warrant are each $0.04 per share. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2030-06-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-01 · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · Balance Not disclosed F5: The Reporting Person purchased a convertible promissory note in the principal amount of $100,000 and an accompanying five-year warrant to purchase 1,250,000 shares of common stock, for a total purchase price of $100,000. The conversion price of the note and exercise price of the warrant are each $0.04 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: 32,500,000 of the shares of restricted stock vest in equal monthly installments over a two-year period.
F2: 100% of the shares subject to the option are fully vested and exercisable.
F3: The stock options are fully vested and exercisable.
F4: Restricted stock units convert into shares of common stock on a one-for-one basis. The restricted stock units will vest in three equal installments, with 25,000 shares of common stock vesting on October 10, 2024, 25,000 shares of common stock vesting on January 10, 2025, and 25,000 shares vesting on the date of the 2025 annual meeting of the Issuer's stockholders.
F5: The Reporting Person purchased a convertible promissory note in the principal amount of $100,000 and an accompanying five-year warrant to purchase 1,250,000 shares of common stock, for a total purchase price of $100,000. The conversion price of the note and exercise price of the warrant are each $0.04 per share.
F6: The grant of stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The stock options shall vest in equal monthly increments over two years, with the first vesting date to occur on November 9, 2025, subject to continued service as a director of the Issuer on each applicable vesting date and the execution of the Issuer's Stock Option Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2013 Filed Feb 27, 2013 22:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 1,289 | $42.52 | $54,808.28 |
DisclosureSEC source: 0001225208-13-005770 · doc4.xml · nonDerivative · entry 1 Golestani Clark · CIK 0001563786 · EVP & Chief Info Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,233 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/10. Performance shares were paid out at 107 percent of target awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.